Published • loading... • Updated
Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
CryptoSlateReposted by 
BITRSS
BITRSSBiotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug
Enlivex, a Nasdaq-listed biotechnology company, is asking shareholders to authorize up to $800 million of financing tied to the RAIN crypto token. The structure could increase its share count by as much as 951%. Despite Enlivex's biotech business, the financing is primarily a crypto-treasury transaction. RAIN delivered at closing would go to the company's treasury wallets, while substantially all cash or stablecoin proceeds are earmarked to acqu…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
